IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...